| Followers | 843 |
| Posts | 123010 |
| Boards Moderated | 9 |
| Alias Born | 09/05/2002 |
Monday, April 17, 2023 11:04:01 AM
PCVX +16% on phase-2 data for VAX-24:
https://finance.yahoo.com/news/vaxcyte-reports-positive-data-phase-103000816.html
https://investors.vaxcyte.com/static-files/90fd9df6-3990-4954-acd8-8e24690783a0
VAX-24 is a 24-valent-pneumococcal vaccine.
Please see #msg-170872992 and #msg-170868559 for background info.
https://finance.yahoo.com/news/vaxcyte-reports-positive-data-phase-103000816.html
https://investors.vaxcyte.com/static-files/90fd9df6-3990-4954-acd8-8e24690783a0
VAX-24 is a 24-valent-pneumococcal vaccine.
Please see #msg-170872992 and #msg-170868559 for background info.
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent PCVX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2026 08:12:51 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 08:08:31 PM
- Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/06/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 09:37:53 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/01/2026 08:17:46 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/30/2026 06:24:11 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 08:07:55 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/23/2026 08:06:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/08/2026 08:32:44 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/07/2026 08:24:11 PM
- Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/03/2026 08:06:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/01/2026 08:08:55 PM
- Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults • GlobeNewswire Inc. • 03/23/2026 12:30:00 PM
- Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate • GlobeNewswire Inc. • 03/18/2026 11:34:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 11:03:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/17/2026 08:16:12 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/11/2026 09:25:23 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/10/2026 08:12:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 01:08:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 01:07:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/03/2026 01:06:44 AM
